Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor which is being combined here to further augment the immune activity of the vaccine. Citarinostat has not been approved by the FDA as a treatment for any disease.

SparkCures ID 207
Developed By Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Generic Name Citarinostat
Additional Names ACY-241, CC-96241
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Multiple Myeloma
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.